Drug-drug Interaction Study With AZD5335 and Itraconazole in Participants With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

This is a non-randomized, open-label, fixed sequence study to be conducted at multiple study centers. The study will consist of 2 parts: Part A of the study will comprise of: * Screening period * Treatment period: The treatment period will comprise of Cycles 1, 2 and 3 where the participants will receive AZD5335 along with itraconazole * Follow-up visit (not applicable for participants involved in Part B) Part B of the study will comprise of: * Treatment period: Cycle 4 and onwards * Safety Follow-up period